膜杰作
Star Staining
- Genetically modified cell lines best reflect MOA (Mechanism of Action)
- Higher activity and larger assay window for robust and reproducible cell-based bioassay
- Comprehensive application data to support assay development and validation
- Full tracible record, stringent quality control and validated cell passage stability
- Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
- Global commercial license assistance whenever regulatory filing is required
描述（Description）
The Human BTLA (Luc) Jurkat Reporter Cell was engineered to not only express the NFAT response element driving luciferase expressing systems, but also express the receptor full length human BTLA (Gene ID: 151888). When cocultured with anti-human BTLA agonist antibody, the interaction of agonist antibody and BTLA on the surface of Human BTLA (Luc) Jurkat Reporter Cell results in a decrease in TCR signaling and NFAT-mediated luminescence.
应用说明（Application）
• Screen for anti-human BTLA agonist antibody.
• Screen for antibody blocking the BTLA/HVEM binding.
生长特性（Growth Properties）
Suspension
筛选标记（Selection Marker）
Puromycin (5 μg/mL) + Hygromycin (20 μg/mL)
培养基（Culture Medium）
1640 medium + 10% FBS
冻存液（Freeze Medium）
Serum-free cell cryopreservation medium
装量（Quantity）
1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium
存储（Storage）
Frozen in liquid nitrogen.
支原体检测（Mycoplasma Testing）
Negative
无菌检测（Sterility Testing）
Negative
使用说明（Instructions for Use）
See data sheet for detailed culturing and assay protocol.
Receptor Assay
Expression analysis of human BTLA on Human BTLA (Luc) Jurkat Reporter Cell by FACS.
Human BTLA (Luc) Jurkat Reporter Cell or negative control cell were stained with PE-labeled anti-human BTLA antibody.
Protocol
Application
Inhibition of TCR activator-induced reporter activity by anti-human BTLA antibody.
This reporter cell was incubated with serial dilutions of antibodies stimulated by TCR activator. The EC50 of anti-human BTLA antibody is approximately 0.0037 μg/mL.
Protocol
Passage Stability
Passage stability analysis by anti-human BTLA antibody stimulation.
The continuously growing Human BTLA (Luc) Jurkat Reporter Cell was stimulated with serial dilutions of antibodies. Anti-human BTLA antibody stimulated response demonstrates passage stabilization (EC50 and neutralization) across passage 5-23.
Protocol
如有相关细胞池需求请联系我们
背景（Background）
B- and T-lymphocyte attenuator (BTLA) is also known as B- and T-lymphocyte-associated protein, CD antigen CD272. BTLA contains one Ig-like V-type (immunoglobulin-like) domain. As a lymphocyte inhibitory receptor, BTLA / CD272 inhibits lymphocytes during immune response. BTLA / CD272 can interact with tyrosine phosphatases PTPN6/SHP-1 and PTPN11/SHP-2, and interact with TNFRSF14/HVEM.
Limited Use&License Disclosure
- This cell line is provided for research use only. It is neither intended for any animal or human therapeutic use nor for any direct human in vivo use. You are restricted to share, modify, transfer, distribute, sell, sublicense, or otherwise make the cell line available for use to other researchers, laboratories, research institutions, hospitals, universities, or service organizations.
- ACROBIOSYSTEMS MAKES NO WARRANTIES OR REPRESENTATIONS OF ANY KIND, EITHER EXPRESSED OR IMPLIED, WITH RESPECT TO THE SUITABILITY OF THE CELL LINE FOR ANY PARTICULAR USE.
- ACROBIOSYSTEMS ACCEPTS NO LIABILITY IN CONNECTION WITH THE HANDLING OR USE OF THE CELL LINE.
- Modifications of the cell line, transfer to a third party, or commercial use of the cell line may require a separate license and additional fees. Please contact order.cn@acrobiosystems.com for further details.
